abrdn plc Acquires Shares of 169,051 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

abrdn plc acquired a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 169,051 shares of the company’s stock, valued at approximately $10,119,000. abrdn plc owned 0.14% of Apellis Pharmaceuticals at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Apellis Pharmaceuticals by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 9,469,977 shares of the company’s stock valued at $360,238,000 after buying an additional 68,687 shares during the period. Jennison Associates LLC lifted its position in shares of Apellis Pharmaceuticals by 79.8% in the 3rd quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock worth $134,746,000 after purchasing an additional 1,571,606 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Apellis Pharmaceuticals by 109.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock worth $128,400,000 after purchasing an additional 1,121,497 shares during the period. Polar Capital Holdings Plc lifted its position in shares of Apellis Pharmaceuticals by 126.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock worth $40,089,000 after purchasing an additional 588,875 shares during the period. Finally, Fiera Capital Corp lifted its position in shares of Apellis Pharmaceuticals by 74.2% in the 3rd quarter. Fiera Capital Corp now owns 919,690 shares of the company’s stock worth $34,985,000 after purchasing an additional 391,770 shares during the period. 96.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on APLS. HC Wainwright reaffirmed a “buy” rating and issued a $92.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday, April 15th. JPMorgan Chase & Co. upped their price target on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Mizuho reaffirmed a “neutral” rating and issued a $60.00 price target on shares of Apellis Pharmaceuticals in a research report on Wednesday, March 27th. The Goldman Sachs Group boosted their price objective on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, January 9th. Finally, Raymond James boosted their price objective on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a research note on Thursday, January 11th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $77.93.

Apellis Pharmaceuticals Trading Down 4.0 %

Shares of Apellis Pharmaceuticals stock opened at $47.93 on Friday. The company has a current ratio of 3.10, a quick ratio of 2.50 and a debt-to-equity ratio of 0.48. Apellis Pharmaceuticals, Inc. has a 12-month low of $19.83 and a 12-month high of $94.75. The firm has a market capitalization of $5.78 billion, a price-to-earnings ratio of -10.70 and a beta of 0.88. The firm’s 50 day simple moving average is $58.61 and its two-hundred day simple moving average is $57.37.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.73). Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The business had revenue of $146.38 million for the quarter, compared to analyst estimates of $143.34 million. During the same quarter in the prior year, the business posted ($1.50) EPS. Apellis Pharmaceuticals’s revenue for the quarter was up 545.9% compared to the same quarter last year. Analysts predict that Apellis Pharmaceuticals, Inc. will post -1.33 EPS for the current year.

Insider Buying and Selling

In related news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director A. Sinclair Dunlop sold 18,681 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $57.18, for a total transaction of $1,068,179.58. Following the transaction, the director now directly owns 173,998 shares of the company’s stock, valued at approximately $9,949,205.64. The disclosure for this sale can be found here. Insiders sold a total of 381,011 shares of company stock valued at $23,463,657 over the last 90 days. Insiders own 7.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).